NATCO Pharma Ltd. moves to reshape its capital structure

Approximately 17.05 million shares, or 1.71 crore shares, would be issued.

Calculation:

• Issue proceeds: Rs 1,279 crore
• Issue price: Rs 750 per share
• New shares = Rs 1,279 crore ÷ Rs 750 = 1.705 crore shares

Natco Pharma’s current paid-up equity capital is Rs 35.80 crore ^[1], with a face value of Rs 2 per share ^[2], implying approximately 17.91 crore existing shares.

• New shares as a percentage of existing shares: 1.705 ÷ 17.911 = 9.52%
• Existing shareholders’ post-issue ownership dilution: 1.705 ÷ (17.911 + 1.705) = 8.69%

Thus, the issue represents 9.52% of the current share base, while existing shareholders’ ownership would reduce to approximately 91.31% of the enlarged equity base.

Natco’s Rs 1,279.36 Crore rights issue at Rs 750 per share represents a clear shift toward primary equity funding, rather than a continuation of its recent funding pattern. In FY25-FY26, operating cash flow was substantially above reported capex, equity share capital was unchanged, and the main balance-sheet change was higher borrowing. The issue also appears substantially larger than any previously disclosed annual capex requirement.

Funding mix: recent history versus the rights issue

Operating cash flow covered capex by approximately 4.23x in FY25 and 4.55x in FY26, derived from the reported figures above. This suggests that the company’s recent investment spending was principally supportable through internal cash generation, even though FY26 also saw higher debt.

By contrast, the proposed issue involves 1,70,58,082 shares at Rs 750 each, aggregating up to Rs 1,279.36 Crores, with a rights ratio of 2 shares for every 21 held ^[13]. At full subscription, shares outstanding would increase from 17.91 Crores to 19.62 Crores, implying approximately 9.52% gross share-count expansion, derived from the disclosed pre- and post-issue shares ^[14]. The issue price includes a Rs 748 premium over the Rs 2 face value ^[13]. It is approximately 2.91x FY26 consolidated book value per share of Rs 257.57, derived from the issue price and reported book value ^[15].

Does it align with prior capex guidance?

Not on the evidence currently available. The earlier Q3 FY26 management-call summary reported no explicit current capex or strategic-investment plan, and no specific manufacturing capex programme was detailed. Potential future financing was discussed in the context of large acquisitions, with cash, debt and equity as possible funding sources ^[16].

The issue is approximately 3.29x FY26 consolidated capex, derived from Rs 1,279.36 Crores of proposed proceeds ^[13] and Rs 388.3 Crores of FY26 capex ^[9]. However, the rights-issue approval itself specifies the size, price and entitlement terms but does not allocate the proceeds to a named capex project ^[13].

Analytical conclusion: the rights issue is best viewed as a broad strategic-capital raise—potentially providing capacity for acquisitions, expansion or balance-sheet flexibility—rather than as funding clearly matched to a previously disclosed FY27/FY28 capex budget. The decisive missing evidence is the final use-of-proceeds disclosure in the offer document or subsequent management commentary.